Aura Biosciences, Inc. AURA
Institutional shares held
37.6 Million
122K
calls
38.5K
puts
Total value of holdings
$298M
$967K
calls
$305K
puts
Market Cap
$232M
29,273,600
Shares Out.
Institutional ownership
128.37%
# of Institutions
88
We take great care to ensure that the data presented and summarized in this overview for Aura Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AURA
View all-
Matrix Capital Management Company, LP Waltham, MA6.92MShares$54.9 Million2.94% of portfolio
-
Eventide Asset Management, LLC Boston, MA5.8MShares$46 Million0.91% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.88MShares$38.7 Million0.08% of portfolio
-
Medicxi Ventures Management (Jersey) LTD3.04MShares$24.1 Million5.49% of portfolio
-
Black Rock Inc. New York, NY3.01MShares$23.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.81MShares$14.3 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.67MShares$13.2 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.27MShares$10.1 Million0.67% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC1.16MShares$9.22 Million5.77% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR1.13MShares$8.99 Million0.37% of portfolio
Latest Institutional Activity in AURA
Top Purchases
Top Sells
About AURA
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at AURA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 21
2025
|
Pinos Elisabet De Los |
SELL
Open market or private sale
|
Direct |
15,955
-4.98%
|
$111,685
$7.67 P/Share
|
|
Jan 21
2025
|
Amy Elazzouzi Vice President, Finance |
SELL
Open market or private sale
|
Direct |
1,001
-2.54%
|
$7,007
$7.67 P/Share
|
|
Nov 18
2024
|
Janet Jill Hopkins Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,822
-7.23%
|
$106,398
$9.36 P/Share
|
|
Oct 29
2024
|
Pinos Elisabet De Los |
SELL
Open market or private sale
|
Direct |
9,200
-2.79%
|
$92,000
$10.74 P/Share
|
|
Oct 29
2024
|
Amy Elazzouzi Vice President, Finance |
SELL
Open market or private sale
|
Direct |
553
-1.38%
|
$5,530
$10.74 P/Share
|
|
Oct 18
2024
|
Julie B Feder Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,131
-15.77%
|
$301,572
$12.03 P/Share
|
|
Oct 18
2024
|
Julie B Feder Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,131
+5.02%
|
$100,524
$4.16 P/Share
|
|
Oct 18
2024
|
Pinos Elisabet De Los |
SELL
Open market or private sale
|
Direct |
24,992
-7.04%
|
$299,904
$12.04 P/Share
|
|
Oct 18
2024
|
Pinos Elisabet De Los |
BUY
Exercise of conversion of derivative security
|
Direct |
24,992
+6.58%
|
$49,984
$2.74 P/Share
|
|
Oct 16
2024
|
Mark Plavsic Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
7,383
-5.74%
|
$66,447
$9.85 P/Share
|
|
Sep 27
2024
|
Pinos Elisabet De Los |
BUY
Exercise of conversion of derivative security
|
Direct |
5,474
+1.63%
|
$27,370
$5.76 P/Share
|
|
Jun 20
2024
|
David Michael Johnson |
BUY
Grant, award, or other acquisition
|
Direct |
10,500
+6.7%
|
-
|
|
Jun 20
2024
|
Sapna Srivastava |
BUY
Grant, award, or other acquisition
|
Direct |
10,500
+50.0%
|
-
|
|
Jun 20
2024
|
Antony C. Mattessich |
BUY
Grant, award, or other acquisition
|
Direct |
10,500
+50.0%
|
-
|
|
Apr 02
2024
|
Conor Kilroy General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
96,000
+50.0%
|
-
|
|
Feb 01
2024
|
Pinos Elisabet De Los |
BUY
Grant, award, or other acquisition
|
Direct |
162,935
+33.44%
|
-
|
|
Feb 01
2024
|
Julie B Feder Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,285
+34.68%
|
-
|
|
Feb 01
2024
|
Janet Jill Hopkins Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,515
+14.85%
|
-
|
|
Jan 23
2024
|
Pinos Elisabet De Los |
SELL
Open market or private sale
|
Direct |
15,853
-8.94%
|
$110,971
$7.64 P/Share
|
|
Jan 23
2024
|
Julie B Feder Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,609
-9.5%
|
$46,263
$7.64 P/Share
|
Last 12 Months Summary
Buy / Acquisition
183K
Shares
From
6
Insiders
| Grant, award, or other acquisition | 128K shares |
|---|---|
| Exercise of conversion of derivative security | 55.6K shares |
Sell / Disposition
96K
Shares
From
5
Insiders
| Open market or private sale | 96K shares |
|---|